Proactive Tight Monitoring of Patients with Inflammatory Bowel Disease in Biological Therapy: A Controlled Clinical Study (TIME IT)
Katrine Risager Christensen, Osamah S. A. Al-Obaidi, Sine Buhl, Johan F. Ilvemark, Casper Steenholdt, Jørn Brynskov, Mark A. Ainsworth · 2026
Read Proactive Tight Monitoring of Patients with Inflammatory Bowel Disease in Biological Therapy: A Controlled Clinical Study (TIME IT) by Katrine Risager Christensen, Osamah S. A. Al-Obaidi, Sine Buhl, Johan F. Ilvemark, Casper Steenholdt, Jørn Brynskov, Mark A. Ainsworth (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13565967.txt.
Description
Katrine Risager Christensen and six co-authors test proactive, scheduled monitoring for people with inflammatory bowel disease (IBD) on biologic therapy. Scheduled checks hunt hidden disease activity and allow timely dose changes, while reactive care waits for decline. Their 2026 study followed 91 proactively monitored patients for one year, against 71 matched reactive-care patients at another center. Everyone had a colonoscopy at year's end.
Treatment failure — poor healing or control, surgery, or stopping the drug — hit 74 percent of the monitored group and 85 percent of the reactive group in the full count. The gap fell short of firm proof. In the clean-run set it ran 64 against 81 percent, still not firm. Proactive care also cost far more visits and tests for that soft edge.
Catalog record
| CREATOR | Katrine Risager Christensen, Osamah S. A. Al-Obaidi, Sine Buhl, Johan F. Ilvemark, Casper Steenholdt, Jørn Brynskov, Mark A. Ainsworth |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |